

June 30, 2004

For Further Information:

Yukiko Miyake-Hashitera  
Director, Business Management  
**R-Tech Ueno, Ltd.**  
Tel. : (079) 560-7181  
Fax : (079) 560-7180

Hideo Shiba  
Director, Corporate Communications  
**Fujisawa Pharmaceutical Co., Ltd.**  
Tel. : (06) 6206-7857  
Fax : (06) 6206-5016

### **R-Tech Ueno Will Start Marketing Rescula<sup>®</sup> Eye Drops in Japan**

Japan, June 30, 2004 - R-Tech Ueno, Ltd. (R-Tech Ueno) and Fujisawa Pharmaceutical Co., Ltd. (Fujisawa) today announced that the marketing agreement for Rescula<sup>®</sup> Eye Drops, an anti-glaucoma and anti-ocular hypertension agent, in Japan will be terminated and R-Tech Ueno will start marketing the product from October 1, 2004.

Rescula<sup>®</sup> Eye Drops is the world's first metabolic-type prostaglandin-related product for the treatment of glaucoma and ocular hypertension. The drug was developed by Ueno Fine Chemicals Industry Ltd. (Ueno Fine Chemicals) with technological supports from R-Tech Ueno. Fujisawa acquired exclusive marketing rights for Rescula<sup>®</sup> Eye Drops in Japan from Ueno Fine Chemicals and has marketed it since 1994. In 2001, R-Tech Ueno took over the NDA (New Drug Application) of the drug from Ueno Fine Chemicals and Fujisawa concluded a new agreement with R-Tech Ueno to acquire the exclusive marketing rights in Japan, Taiwan and Korea. Since then, Fujisawa has been marketing the product in Taiwan through Fujisawa Taiwan Co., Ltd. and in Korea through a local partner.

R-Tech Ueno, with Rescula<sup>®</sup> Eye Drops as its lead sales product, intends to expand its ophthalmology business in Japan. After discussions, the two companies have agreed that the marketing agreement for Rescula<sup>®</sup> Eye Drops in Japan will be terminated on September 30, 2004 and R-Tech Ueno will start marketing the product in Japan from October 1, 2004. Fujisawa will retain the exclusive marketing rights for the drug in Taiwan and Korea.

Rescula<sup>®</sup> Eye Drops has good safety profiles with few serious side effects, topically or systemically. Administered twice daily, it reduces elevated intraocular pressure and maintains long-term visual field. Because of its superior efficacies in both glaucoma (including normal and/or low tension glaucoma) and ocular hypertension treatments, Rescula<sup>®</sup> Eye Drops has been highly recognized among the medical communities for 10 years since its launch.

The profile of R-Tech Ueno, Ltd. is as follows.

**R-Tech Ueno, Ltd.**

Established:	September 1989
Location:	4-1 Techno-Park, Sanda, Hyogo, Japan
Representative Director:	Mitsunaga Tada
Capital:	257 million yen
Revenue:	4 billion yen (2003)
Employees:	Approximately 60
Principal Business:	Development, research, manufacture and import/export of pharmaceuticals
Website Address:	<a href="http://www.rtechueno.com">http://www.rtechueno.com</a>

#####